InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for up to C$1,050,000

NOT FOR DISTRIBUTION TO U.S NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, British Columbia, Feb. 25, 2015 /CNW/ – InMed Pharmaceuticals, Inc. (“InMed”) (CSE: IN; OTCQB: IMLFF), is pleased to promulgate that it has closed the non-brokered special placement for 10,500,000 units (“Units”) at a cost of $0.10 per Unit (the “Financing”).  Each Unit consists of undivided common share and one non-transferable have part purchase warrant.  Each whole sanction will be exercisable by the owner to acquire one additional common experience at a price of $0.13 as being a period of twenty four (24) months following the closing of the financing.

Finders’ fees of 10% ~ward a portion of the gross income received by the Company from the opportunity to sell of Units sold pursuant to the Financing shall contain cash of ($78,550.00) and 785,500 warrants (“Agent Warrants”).   Each Agent Warrant shall subsist exercisable in whole or in sub-division at an exercise price of $0.13 on the side of a period of 24 months from the closing of the Financing.

The clear proceeds from this private placement disposition be used for general working first-rate purposes. All securities issued pursuant to the Financing wish be subject to a four month and person day hold period from the era of closing of the Financing.

About InMed

InMed is a clinical platform biopharmaceutical company that specializes in developing modern therapies through the research and disentanglement into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated progressive growth pathway are the fundamental value drivers of the visitors. For more information, visitwww.inmedpharma.com

ON BEHALF OF THE BOARD

InMed Pharmaceuticals Inc.
Craig Schneider
President and Chief Executive Officer
T: 604.669.7207
F: 604.683.2506
E: info@inmedpharma.com

Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (Investors)
jdrumm@tiberend.com
212-375-2664
Amy Wheeler (Media)
awheeler@tiberend.com
646-362-5750

Forward Looking Statements

This recent accounts release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) in the limits of the meaning of applicable securities laws.  Forward-looking advice is based on management’s current expectations and beliefs and is subject to a consist of of risks and uncertainties that could incitement actual results to differ materially from those described in the head-looking statements.  Forward-looking accusation in this news release includes statements from one place to another the use of net proceeds from the solitary placement and the expected fundamental estimate drivers of the company. Although in the same state statements are based on management’s equitable assumptions, there can be no pledge of certainty that such assumptions will prove to be correct.  Such statements involve known and mystic risks, uncertainties and other factors that may cause actual results, performance or achievements to exist materially different from those implied ~ means of such statements. Known risk factors hold, among others: InMed may not employment net proceeds received from the privy placement as currently contemplated and InMed’s proprietary platform technology, product pipeline and accelerated disclosure pathway may not return their expected plain of value.

A more complete ventilation of the risks and uncertainties facing InMed is disclosed in InMed’s unintermitted disclosure filings with Canadian securities regulatory magistrates at www.sedar.com. All favor-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims in ~ degree obligation to revise or update in ~ degree such forward-looking information or to publicly proclaim the result of any revisions to somewhat of the forward-looking information contained in this to reflect future results, events or developments, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE InMed Pharmaceuticals Inc.

Copyright © 2015 PR Newswire. All Rights Reserved

No hog flu vaccine works as well during the time that vitamin D to protect you from influenza.

Search keywords

Recent Comments

    Archives